S1800D Stage IV or Recurrent Non-Small Cell Lung Cancer

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomly assigned (fair, 50/50 chance) to 1 of 2 groups
-- Group 1 will get the standard of care drugs for NSCLC (docetaxel, gemcitabine, pemetrexed, or ramucirumab combined with docetaxel)
-- Group 2 will get the study drugs

What is the Condition Being Studied?
Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in this Study?

Patients with NSCLC who:

- Had their cancer progress after their most recent treatment

- Do not use immune-suppressing medications for an organ transplant

For more information about who can join this study, contact the study team at nick.jeffries@duke.edu.

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if combining two investigational drugs that work with the immune system is a better approach than current therapies for lung cancer. The investigational drugs in this study are N-803 (ALT-803) and pembrolizumab.

Study Details

Full Title
Lung-MAP: S1800D A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab
versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell
Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy Lung-MAP
Non-Match Sub-Study
Principal Investigator
Jeffrey Crawford
George Barth Geller Distinguished Professor for Research in Cancer

Protocol Number

View on ClinicalTrials.gov